Shares of Seattle-based Dendreon got a boost on Wednesday when the biotech company announced it would file for FDA marketing approval for its new prostate cancer drug Provenge. Dendreon officials said that in talks with agency officials, the FDA said that the data from two Phase III trials for Provenge could support an NDA. Trial results from earlier in the year showed that patients taking Provenge had longer survival times compared to a placebo.
- read this story from the Seattle Post-Intelligencer for more